TIANFUCHEM--202467-69-4--High purity 3-[[[(2S,4S)-4-Mercapto-1-(4-nitrobenzyloxy)carbonyl-2-pyrrolidinyl]carbonyl]amino]benzoic acid factory price CAS NO.202467-69-4

3 - [[[(2s, 4s) -4-mercapto-1- (4- nitrobenzyloxy) carbonyl-2-pyrrolidinyl] carbonyl] amino]

english synonyms: 3 - ([(2s, 4s) -4-mercapto-1 - (4-nitrobenzyloxy) carbonyl] amino) benzoic acid; ertapenem side chain, side chain for ertapenem; ertapenem side chains; side train of ertapenem; 2 - [[(3-carboxyphenyl) amino] carbonyl] amino] ] carbonyl] -4-mercapto-1-pyrrolidinecarboxylic acid (2s-cis) -1 - [(4-nitrophenyl) methyl] 2-pyrrolidinyl-1- (4-nitrobenzyloxy) carbonyl] carbonyl] amino] benzoic acid (3-nitrobenzyloxy) carbonyl-2-pyrrolidinyl] carbonyl]

cas no .: 202467-69-4

molecular formula: c20h19n3o7s

molecular weight: 445.45

einecs number:

related categories: intermediates; pharmaceutical raw materials; pharmaceutical intermediates

mol file: 202467-69-4.mol

ertapenem south side chain

ertapenem side chain properties

cas database 202467-69-4 (cas database reference)

ertapenem side chain usage and synthesis method

background and overview carbapenem antibiotics are new β-lactam antibiotics, β-lactamase stable. antibacterial spectrum is divided into 3 types. type 1: broad spectrum carbapenems have limited antibacterial activity against non-fermented gram-negative bacilli such as ertapenem for community-acquired infections. type 2: broad spectrum and has antibacterial activity against non-fermented gram-negative bacilli, such as imipenem and meropenem, for use in hospital-acquired infections. type 3: clinical antimicrobial resistance staphylococcus aureus, currently not yet available. carbapenem antibiotics can be effectively used for multi-drug-resistant bacterial infections caused by moderate and severe, is considered to be an important line of defense against infection in humans. with the increasingly serious problem of bacterial resistance, people pay more and more attention to carbapenem antibiotics. among the pei'nan cultivars that have been marketed, ertapenem is a very distinctive one. because of the benzoic acid structure in the structure, it has a long plasma half-life, making it a novel, parenteral, long-acting , a new broad-spectrum carbapenem antibiotic that is stable to dhp-1.

the chemical name of ertapenem is (1r, 5s, 6s, 8r, 2s *, 4s *) - 2- [2- [3- carboxy-phenylcarbamoyl] -pyrrolidinyl-4- thio] -6- (1-hydroxyethyl) -1-methylcarbapenem-3-carboxylic acid monosodium salt, developed by merck, in november 2001 and april 2002 respectively in the united states and listed in europe, followed by the united kingdom, ireland, israel and the philippines listed in china in 2005 listed. this product has good antibacterial activity and pharmacokinetic properties, long half-life, once a day medication can be satisfied with the results of gram-positive bacteria, gram-negative bacteria, aerobic and anaerobic bacteria are good has antimicrobial activity against both cephalosporin-resistant esbls or ampc and penicillin-resistant streptococcus pneumoniae and has been approved for the treatment of adult-complicated intra-abdominal infections. community-acquired pneumonia complicated skin tissue infections complicated urinary tract infections and gynecological infections, etc., and can be used for young children over 3 months, thus having great market potential.